$7.49
+0.10(1.42%)
Mkt Cap $583M
$2.52
$8.18
52-Week Range
At a Glance
AI-generatedSolid Biosciences Inc.
8-K
Solid Biosciences Inc. announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 as of February 23, 2026, showing robust microdystrophin expression, restored beta-sarcoglycan and nNOS activity, biomarker improvements, and stabilization in cardiac function across 40 dosed participants. The company aligned with FDA on Phase 3 IMPACT DUCHENNE trial design, with first dosing anticipated in Q1 2026.$583M
Market Cap
—
Revenue
-$143M
Net Income
Employees100
Fundamentals
How The Business Makes Money
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001707502
ISINUS83422E2046
CUSIP83422E105
Phone617 337 4680
Address141 Portland Street, Cambridge, MA, 02139, US
SEC EDGAR